PsA and difficult-to-treat areas are common among patients with psoriasis And more top psoriasis posters from the Las Vegas Dermatology Seminar IL inhibitor options move psoriasis treatment forward Long-term data continue to support the safety and effectiveness of IL-17 and IL-23 inhibitor drugs. Bingham_Clifton_BALTIMORE_web.jpg Patient outcome questionnaires take a beating in talk LAS VEGAS – Too many patient-reported outcome surveys don’t ask the right questions, but there’s a good alternative, says Clifton O. Bingham III, MD. Murray_Joseph%20A_Rochester%20MN_web.jpg New insight into celiac disease: What you should know LAS VEGAS – Celiac disease, which can mimic rheumatic symptoms, is more common and variable than previously believed. Henoch_Schonlein_purpura_web.jpg IgA vasculitis may be more common in adults than assumed LAS VEGAS – Diagnosis and treatment of IgA vasculitis remain challenging, particularly in adults, and early monitoring is crucial. Coping with a rheumatology clinic’s ‘worst nightmare’ LAS VEGAS – GPA remission is difficult to maintain, rheumatologist says, and close monitoring is crucial. Mandell_Brian_Cleveland_web.jpg Stop treating gout and start curing it, physician urges LAS VEGAS – Doctors are too unwilling, Dr. Brian F. Mandell says, to up-titrate medication to lower serum uric acid. Eichenfield_Lawrence_F_of_CA_web.jpg Psoriasis duration reflects cardiovascular event risk For every year of psoriasis, a patient’s risk of a major cardiovascular event climbs an additional 1%. Leonardi_Craig_L_MO_web_crop.jpg Is PASI 100 the new benchmark in psoriasis? KAUAI, HAWAII – “I think we should just do away with PASI 90 and look at how well our drugs do against the metric of PASI 100.” Wu_Jashin_J_of_CA_web.jpg How to avoid severe diarrhea from apremilast Delayed up-titration of apremilast is often effective, albeit at cost of slower efficacy. Pages« first ‹ previous 1 2 3 4 5 6 next › last »
